Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.53 |
| ▸ | IL6 | P05231 | 9/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26357642 | 0.89 | TLR7 (0.49) | TLR7IL6TLR8 | |
| SCHEMBL26354074 | 0.89 | TLR7 (0.66) | TLR7IL6TLR8 | |
| SCHEMBL26357709 | 0.89 | TLR7 (0.56) | TLR7IL6TLR8 | |
| SCHEMBL29034529 | 0.88 | TLR7 (0.53) | TLR7IL6TLR8 | |
| SCHEMBL26358730 | 0.82 | TLR7 (0.51) | TLR7IL6TLR8 | |
| SCHEMBL26358175 | 0.82 | TLR7 (0.59) | TLR7IL6TLR8 | |
| SCHEMBL26358657 | 0.82 | TLR7 (0.57) | TLR7IL6TLR8 | |
| SCHEMBL29034547 | 0.82 | TLR7 (0.57) | TLR7IL6TLR8 | |
| SCHEMBL26358692 | 0.81 | TLR7 (0.49) | TLR7IL6TLR8 | |
| SCHEMBL29475652 | 0.81 | TLR7 (0.65) | TLR7IL6TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4199968-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | Ambrx, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885IL6 1194/4885BCHE 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.